eli lilly retatrutide clinical trials VisualAbstract: reduces body weight by 17.5% in patients with obesity New Weight Loss Drug Retatrutide:

It should be emphasized, however, that the STEP-HFpEF trial was not designed or powered to assess clinical events, and the impact of semaglutide on hard endpoints in heart failure remains to be determined

Retatrutide dosage: How retatrutide might be taken Since retatrutide hasnt been approved yet, there is still no official prescribing information available today

Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-

July 7, 2025 New Study Links Ozempic and Wegovy to Vision Loss Risk A new study published in JAMA Ophthalmology has linked Ozempic and Wegovy to a higher risk of developing neovascular age-related macular degeneration (nAMD), a serious condition that can lead to permanent vision loss

and programs to increase affordability for lower-wage workers

Competing interests MJD reported board membership and consultancy fees from Novo Nordisk, Sanofi-Aventis, Lilly, Merck, Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, Servier, and Janssen